Stability of vancomycin hydrochloride employed in antimicrobial seal solutions of central intravenous catheters

Abstract Objective: to verify the stability of vancomycin hydrochloride in antimicrobial seal solutions with and without association of heparin sodium according to temperature and association time. Method: an experimental study designed for the analysis of hydrogenionic potential and concentration by means of high-efficiency liquid chromatography of vancomycin hydrochloride (n=06) and vancomycin hydrochloride and heparin sodium (n=06). The solutions studied were submitted to absence of light, as well as to 22°C and 37°C. Analyses in triplicate (n=192) were performed at the initial moment (T0) and three (T3), eight (T8) and 24 hours (T24) after preparation. The data were submitted to analysis of variance (p≤0.05). Results: concentration of the antimicrobial at 22°C presented a reduction (T0-T8) and a subsequent increase (T24); hydrogenionic potential decreased significantly over time. At 37°C, the concentration increased up to T3 and decreased at T24, with a reduction of hydrogenionic potential up to 24 hours. Concentration of the vancomycin hydrochloride and heparin sodium solutions varied with a reduction at 22°C, accompanied by increased hydrogenionic potential. Precipitate formation was observed by visual inspection of the vancomycin hydrochloride-heparin sodium association (T3). Conclusion: pharmacological stability of vancomycin hydrochloride (5 mg/mL) and physical incompatibility with heparin sodium (100 IU/mL) were evidenced after three hours of association in the antimicrobial seal solutions studied.

[1]  L. Björkhem-Bergman,et al.  Equal effect of vancomycin lock with or without heparin in treatment of central venous catheter related blood stream infections – an observational study in palliative home care , 2021, Infectious diseases.

[2]  Lian Zhang,et al.  Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants , 2020, BMC Pediatrics.

[3]  A. Herranz-Alonso,et al.  Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety , 2020, Drugs in R&D.

[4]  R. Ford,et al.  The microbial biofilm composition on peripherally inserted central catheters: A comparison of polyurethane and hydrophobic catheters collected from paediatric patients , 2020, The journal of vascular access.

[5]  R. Faria,et al.  Economic analysis of the prevalence and clinical and economic burden of medication error in England , 2020, BMJ Quality & Safety.

[6]  J. Foushee,et al.  Physical Compatibility of Medications Used in Critically Ill Patients with Balance Fluid Solutions. , 2020, International journal of pharmaceutical compounding.

[7]  S. Aishwarya,et al.  Intravenous Drug Incompatibilities in the Intensive Care Unit of a Tertiary Care Hospital in India: Are they Preventable? , 2020, Journal of research in pharmacy practice.

[8]  S. Genay,et al.  Evaluation of the stability of vancomycin solutions at concentrations used in clinical services. , 2020, European journal of hospital pharmacy : science and practice.

[9]  E. Bouza,et al.  Can vancomycin lock therapy extend the retention time of infected long‐term catheters? , 2020, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  Janine Clarke,et al.  Incidence and prevalence of intravenous medication errors in the UK: a systematic review , 2018, European journal of hospital pharmacy : science and practice.

[11]  M. Akash,et al.  Chemical Kinetics and Its Applications in Drug Stability , 2020 .

[12]  I. Imran,et al.  Principles of Pharmaceutical Analysis in Drug Stability and Chemical Kinetics , 2020 .

[13]  G. Roshandel,et al.  Medication Errors and Their Relationship with Care Complexity and Work Dynamics , 2019, Open access Macedonian journal of medical sciences.

[14]  C. McInnes,et al.  Compatibility and Stability of Daptomycin Lock Solutions in Combination with Gentamicin, Azithromycin, Heparin and Trisodium Citrate , 2019 .

[15]  S. Genay,et al.  Clinical implications of intravenous drug incompatibilities in critically ill patients. , 2019, Anaesthesia, critical care & pain medicine.

[16]  F. Qamar,et al.  Clinical profile and outcome of antibiotic lock therapy for bloodstream infections in pediatric hematology/oncology patients in a tertiary care hospital, Karachi, Pakistan , 2019, International journal of pediatrics & adolescent medicine.

[17]  V. Anttila Central venous catheter care for children with cancer should focus on early infections , 2018, Acta paediatrica.

[18]  S. Begum,et al.  PHARMACEUTICAL INCOMPATIBILITES: A REVIEW , 2018, Asian Journal of Pharmaceutical Research and Development.

[19]  V. Piriou,et al.  Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units , 2018, European Journal of Clinical Pharmacology.

[20]  J. Bednar,et al.  Antimicrobial efficiency and stability of two decontamination solutions , 2018, Cell and Tissue Banking.

[21]  E. Abdala,et al.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria , 2018, Antimicrobial Agents and Chemotherapy.

[22]  S. Gul,et al.  Potential Drug–Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Point-Prevalence Study , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[23]  E. Troster,et al.  Risk factors for vascular catheter-related bloodstream infections in pediatric intensive care units , 2018, Revista Brasileira de terapia intensiva.

[24]  M. Ardura Overview of Infections Complicating Pediatric Hematopoietic Cell Transplantation. , 2018, Infectious disease clinics of North America.

[25]  Katri Vehviläinen-Julkunen,et al.  Differences Between Methods of Detecting Medication Errors: A Secondary Analysis of Medication Administration Errors Using Incident Reports, the Global Trigger Tool Method, and Observations , 2016, Journal of patient safety.

[26]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  F. Burczynski,et al.  Antibiotic‐Heparin Lock: In Vitro Antibiotic Stability Combined with Heparin in a Central Venous Catheter , 2000, Pharmacotherapy.

[28]  W. Rusho,et al.  Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  C L Rümke,et al.  [Incidence and prevalence]. , 1983, Nederlands tijdschrift voor geneeskunde.

[30]  A. Hirschfelder THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .